Etrusco Andrea, Agrifoglio Vittorio, Laganà Antonio Simone, Gliozheni Elko, Caringella Annamaria, Stanziano Antonio, Cicinelli Ettore, Chiantera Vito, Giannini Andrea, Alsannan Baydaa, Barra Fabio, D'Amato Antonio
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Piazza Marina, 61, Palermo 90133, Italy.
Unit of Obstetrics and Gynecology, "Paolo Giaccone" Hospital, Palermo, Italy.
Ther Adv Reprod Health. 2024 Sep 23;18:26334941241271563. doi: 10.1177/26334941241271563. eCollection 2024 Jan-Dec.
Uterine sarcomas (US) are rare cancer of possible occurrence even in women of childbearing age. To date, total hysterectomy is the standard treatment in the early stages. The possibilities of carrying out fertility-sparing treatments (FST) to save the fertility of women with unfulfilled reproductive desires are described in the literature, but to date, they can only be considered experimental.
The aim of this systematic review was to evaluate the oncological and reproductive outcomes of women with different histological types of US undergoing FST.
Systematic review.
Electronic databases were searched for English-language studies describing FST for US until January 31, 2024.
Forty-five papers which met the abovementioned inclusion criteria, were included in the qualitative analysis. Quantitative analysis was not possible because of the heterogeneity of the data. A descriptive summary of the results according to the histotype of US was provided. Six hundred forty-one patients of childbearing age with US and undergoing FST. After treatment with FST, 89 (13.9%) disease recurrences and 107 (16.7%) pregnancies were recorded.
In selected cases of early-stage US, FST may be proposed. However, the patient must be informed of the real possibility of recurrence and potentially difficult achievement of pregnancy. Additional well-designed prospective studies and clinical trials are needed to address the knowledge gaps and enhance clinical decision-making in this population.
PROSPERO ID: CRD42024509356.
子宫肉瘤(US)是一种罕见的癌症,甚至在育龄女性中也可能发生。迄今为止,全子宫切除术是早期阶段的标准治疗方法。文献中描述了为有未实现生育愿望的女性实施保留生育功能治疗(FST)以挽救其生育能力的可能性,但迄今为止,这些治疗只能被视为实验性的。
本系统评价的目的是评估接受FST的不同组织学类型US女性的肿瘤学和生殖结局。
系统评价。
检索电子数据库,查找截至2024年1月31日描述US的FST的英文研究。
45篇符合上述纳入标准的论文被纳入定性分析。由于数据的异质性,无法进行定量分析。根据US的组织学类型提供了结果的描述性总结。641名育龄期US女性接受了FST。FST治疗后,记录到89例(13.9%)疾病复发和107例(16.7%)妊娠。
在选定的早期US病例中,可以考虑FST。然而,必须告知患者复发的实际可能性以及怀孕可能面临的困难。需要更多精心设计的前瞻性研究和临床试验来填补知识空白,加强该人群的临床决策。
PROSPERO注册号:CRD42024509356。